{"url_path":"/sec/sbcww/8-k/2026-05-20/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1930313/0001493152-26-024609-index.html","accession_number":"0001493152-26-024609","cik":"0001930313","ticker":"SBC","issuer_name":"SBC Medical Group Holdings Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1930313/0001493152-26-024609-index.html","primary_entity_key":"0001930313","primary_entity_name":"SBC Medical Group Holdings Inc"},"word_count":351,"has_tables":true,"body_markdown":"false\n0001930313\n\n0001930313\n\n2026-05-14\n2026-05-14\n\n0001930313\n\nSBC:CommonStock0.0001ParValuePerShareMember\n\n2026-05-14\n2026-05-14\n\n0001930313\n\nSBC:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember\n\n2026-05-14\n2026-05-14\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**WASHINGTON,\nD.C. 20549**\n\n** **\n\n \n\n** **\n\n**FORM\n8-K**\n\n \n\n \n\n \n\n**CURRENT\nREPORT**\n\n**Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n** **\n\n**Date\nof Report (Date of earliest event reported): May 14, 2026**\n\n** **\n\n \n\n** **\n\n**SBC\nMedical Group Holdings Incorporated**\n\n**(Exact\nname of Registrant as Specified in Its Charter)**\n\n** **\n\n \n\n** **\n\n**Delaware**\n \n**001-41462**\n \n**88-1192288**\n\n**(State or Other Jurisdiction\nof Incorporation)**\n \n\n**(Commission**\n\n**File\nNumber)**\n\n \n**(IRS Employer\nIdentification No.)**\n\n****\n\n** **\n\n**200 Spectrum\nCenter Dr., STE 300**\n \n**92618**\n\n**Irvine, California**\n \n**(Zip Code)**\n\n**(Address of Principal Executive\nOffices)**\n \n \n\n** **\n\n**Registrant’s\nTelephone Number, Including Area Code: (949)****593-0250**\n\n \n\n**Not\nApplicable**\n\n**(Former\nName or Former Address, if Changed Since Last Report)**\n\n \n\n \n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule\n425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the\nExchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b)\nunder the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c)\nunder the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n****\n\n** **\n\n**Title of\neach class**\n \n**Trading Symbol(s)**\n \n**Name of each\nexchange on which registered**\n\nCommon Stock, $0.0001 par\nvalue per share\n \nSBC\n \nThe Nasdaq Stock Market\nLLC\n\nRedeemable Warrants, each\nwhole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share\n \nSBCWW\n \nThe Nasdaq Stock Market\nLLC\n\n****\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}